SVRA Stock: Price, Forecast, Financials & AI Analysis

Loading...

Loading chart...

High

5.250

Open

5.080

VWAP

5.16

Vol

2.24M

Mkt Cap

1.07B

Low

5.015

Amount

11.53M

EV/EBITDA(TTM)

--

Total Shares

204.93M

EV

870.38M

EV/OCF(TTM)

--

P/S(TTM)

--

Savara Inc. is a clinical-stage biopharmaceutical company. The Company is focused on rare respiratory diseases. The Company’s lead program, molgramostim inhalation solution (MOLBREEVI or molgramostim), is an inhaled biologic, specifically an inhaled granulocyte-macrophage colony-stimulating factor (GM-CSF) in Phase III development for autoimmune pulmonary alveolar proteinosis (aPAP). MOLBREEVI is an inhaled formulation of recombinant human GM-CSF and is being developed for the treatment of aPAP. MOLBREEVI is administered once daily by inhalation via a high efficiency nebulizer, the eFlow Nebulizer System (PARI Pharma GmbH). Pulmonary alveolar proteinosis (PAP) is a rare lung disease characterized by the accumulation of surfactant in the alveoli (or air sacs) of the lungs. The Company is engaged in the advancement of the MOLBREEVI aPAP program and the Phase III IMPALA-2 clinical trial and outsourcing capital-intensive operations.

Show More

Events Timeline

(ET)

2026-05-20

08:20:00

Savara Presents New Data on Molgramostim at ATS 2026 Conference

2026-05-12 (ET)

2026-05-12

16:30:00

Savara CEO: $150M in Funding Available Upon MOLBREEVI Approval

2026-04-15 (ET)

2026-04-15

16:20:00

Savara Receives FDA Three-Month Extension for Molgramostim Review

2026-04-07 (ET)

2026-04-07

08:20:00

Savara Announces MHRA Acceptance of Molbreevi Application

2026-03-30 (ET)

2026-03-30

08:10:00

Savara Receives EMA Validation for MOLBREEVI Submission

2026-03-13 (ET)

2026-03-13

16:40:00

S&P 500 Declines as Brent Oil Prices Rise Above $100

2026-03-13

12:10:00

Major Averages Lower as Investors Shift to Cash and Short-Term Bonds

2026-03-13

08:50:00

Savara Reports $235.7M Cash Reserves, Optimistic Outlook for 2026

2026-03-06 (ET)

2026-03-06

16:20:00

Savara Receives Day 74 Letter from FDA, MOLBREEVI Application Under Ongoing Review

News

Newsfilter

05-19Newsfilter

Savara Presents Long-Term Efficacy Data for Molgramostim at ATS Conference

Newsfilter

05-18Newsfilter

Savara Presents New Data at ATS 2026 Conference

seekingalpha

05-12seekingalpha

Savara Reports Q1 Earnings Miss with Negative EPS

Newsfilter

04-17Newsfilter

Savara Inc. Grants Inducement Awards to New Employees

seekingalpha

04-16seekingalpha

Savara's FDA Review Period Extended for Molgramostim

stocktwits

04-15stocktwits

Savara's FDA Review for Molgramostim Delayed by Three Months

6 Analyst Rating

Wall Street analysts forecast SVRA stock price to rise

6 Buy

0 Hold

0 Sell

Strong Buy

Current: 0.000

Low

9.00

Averages

10.17

High

11.00

Current: 0.000

Low

9.00

Averages

10.17

High

11.00

Oppenheimer

Mazahir Alimohamed

NULL

to

Outperform

upgrade

$9 -> $11

AI Analysis

2026-04-24

Reason

Oppenheimer

Mazahir Alimohamed

Price Target

$9 -> $11

AI Analysis

2026-04-24

upgrade

NULL

to

Outperform

Reason

Oppenheimer analyst Mazahir Alimohamed assumed coverage of Savara with an Outperform rating with a price target of $11, up from $9. With Priority Review granted to the BLA for molgramostim, an inhaled GM-CSF therapy, Savara's story has shifted toward regulatory execution and commercial positioning, the firm says. Robust data from Phase 3 IMPALA-2 in autoimmune PAP support the BLA package and the firm's view of a high-probability approval story, also given that prior FDA feedback was only CMC-related.

H.C. Wainwright

Andrew Fein

Buy

maintain

$8 -> $10

2025-12-23

Reason

H.C. Wainwright

Andrew Fein

Price Target

$8 -> $10

2025-12-23

maintain

Buy

Reason

H.C. Wainwright analyst Andrew Fein raised the firm's price target on Savara to $10 from $8 and keeps a Buy rating on the shares. The company resubmitted the application for Molbreevi with Fujifilm Diosynth as its drug substance manufacturer, the analyst tells investors in a research note. The firm believes Savara is increasingly well positioned ahead of a potential Molbreevi launch.

Unlock Full Analyst Thesis， Get the complete breakdown of rating reason for SVRA

Unlock Now

Valuation Metrics

The current forward P/E ratio for Savara Inc (SVRA.O) is 0.41, compared to its 5-year average forward P/E of -6.68. For a more detailed relative valuation and DCF analysis to assess Savara Inc's fair value, Click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

dotted line Image

N/A

5Y Average PE

-6.68

Current PE

0.41

Overvalued PE

-3.08

Undervalued PE

-10.29

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

dotted line Image

N/A

5Y Average EV/EBITDA

-0.38

Current EV/EBITDA

0.00

Overvalued EV/EBITDA

4.31

Undervalued EV/EBITDA

-5.06

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

dotted line Image

N/A

5Y Average PS

24.86

Current PS

14.99

Overvalued PS

128.86

Undervalued PS

-79.14

Financials

AI Analysis

Annual

Quarterly

Related Community Screener

5 dollar stock with gain potential

Intellectia · 9 candidates

Market Cap: >= 300.00MPrice: $4.00 - $6.00Volume: >= 1Rsi Category: moderateRelative Vol: >= 1.50Moving Average Relationship: PriceAboveMA20Macd: positive

Ticker

Name

Market Cap$

Immuneering Corp

373.30M

Cadiz Inc

410.34M

LG Display Co Ltd

5.55B

Yext Inc

418.47M

Savara Inc

1.07B

Telos Corp

358.38M

best stock to buy for around $5

Intellectia · 9 candidates

Market Cap: >= 300.00MPrice: $4.00 - $6.00Volume: >= 1Rsi Category: moderateRelative Vol: >= 1.50Moving Average Relationship: PriceAboveMA20Macd: positive

Ticker

Name

Market Cap$

LG Display Co Ltd

5.55B

Savara Inc

1.07B

Arbutus Biopharma Corp

900.77M

Gogo Inc

618.04M

Yext Inc

418.47M

Cadiz Inc

410.34M

stocks predicted to rebound

Intellectia · 14 candidates

Market Cap: >= 1000.00MMoving Average Relationship: PriceCrossAboveMA20One Week Rise Prob: >= 55Macd: bullish

Ticker

Name

Market Cap$

Edwards Lifesciences Corp

46.30B

Beam Therapeutics Inc

2.80B

Centessa Pharmaceuticals PLC

3.58B

Globalstar Inc

7.62B

Aurinia Pharmaceuticals Inc

1.90B

Celldex Therapeutics Inc

1.62B

best potential shorts this week

Intellectia · 8 candidates

Price: $5.00 - $100.00Rsi Category: overbought, moderateMoving Average Relationship: PriceCrossDownMA20One Week Predict Return: -100.0% - -3.0%Monthly Average Dollar Volume: >= 500,000

Ticker

Name

Market Cap$

McKinley Acquisition Corp

244.06M

Essent Group Ltd

5.86B

MGIC Investment Corp

5.78B

Banco Santander Brasil SA

50.15B

Savara Inc

1.14B

Trevi Therapeutics Inc

1.33B

most bullish ticker

Intellectia · 46 candidates

Analyst Consensus: Strong BuyTarget Price Upside Potential: MoreAbovePriceMoving Average Relationship: PriceAboveMA200Option Sentiments: BullishOne Week Rise Prob: >= 70

Ticker

Name

Market Cap$

Tarsus Pharmaceuticals Inc

2.78B

Journey Medical Corp

276.86M

Cytokinetics Inc

7.93B

Abcellera Biologics Inc

1.19B

Savara Inc

1.16B

Taysha Gene Therapies Inc

1.29B

Whales Holding SVRA

TCG Crossover Management, LLC

Nantahala Capital Management, LLC

VR Management, LLC

Deerfield Management Company, L.P.

Vestal Point Capital, LP

Affinity Asset Advisors, LLC

Trading Trends

People Also Watch

Frequently Asked Questions

What is Savara Inc (SVRA) stock price today?

The current price of SVRA is 5.2 USD — it has increased 2.16

What is Savara Inc (SVRA)'s business?

Savara Inc. is a clinical-stage biopharmaceutical company. The Company is focused on rare respiratory diseases. The Company’s lead program, molgramostim inhalation solution (MOLBREEVI or molgramostim), is an inhaled biologic, specifically an inhaled granulocyte-macrophage colony-stimulating factor (GM-CSF) in Phase III development for autoimmune pulmonary alveolar proteinosis (aPAP). MOLBREEVI is an inhaled formulation of recombinant human GM-CSF and is being developed for the treatment of aPAP. MOLBREEVI is administered once daily by inhalation via a high efficiency nebulizer, the eFlow Nebulizer System (PARI Pharma GmbH). Pulmonary alveolar proteinosis (PAP) is a rare lung disease characterized by the accumulation of surfactant in the alveoli (or air sacs) of the lungs. The Company is engaged in the advancement of the MOLBREEVI aPAP program and the Phase III IMPALA-2 clinical trial and outsourcing capital-intensive operations.

What is the price predicton of SVRA Stock?

Wall Street analysts forecast SVRA stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for SVRA is10.17 USD with a low forecast of 9.00 USD and a high forecast of 11.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

What is Savara Inc (SVRA)'s revenue for the last quarter?

Savara Inc revenue for the last quarter amounts to 0.00 USD, decreased

What is Savara Inc (SVRA)'s earnings per share (EPS) for the last quarter?

Savara Inc. EPS for the last quarter amounts to -0.15 USD, increased 25.00

How many employees does Savara Inc (SVRA). have?

Savara Inc (SVRA) has 70 emplpoyees as of May 31 2026.

What is Savara Inc (SVRA) market cap?

Today SVRA has the market capitalization of 1.07B USD.